RT Journal Article
T1 Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus (Orthohepevirus A Genus).
A1 Frias, Mario
A1 Lopez-Lopez, Pedro
A1 Zafra, Ismael
A1 Caballero-Gomez, Javier
A1 Machuca, Isabel
A1 Camacho, Angela
A1 Risalde, Maria A
A1 Rivero-Juarez, Antonio
A1 Rivero, Antonio
K1 HEV RNA
K1 RT-PCR
K1 Limit of detection
K1 Pangenotypic
K1 Performance
K1 Primers
K1 Probe
AB The objective of this study was to design a pangenotypic PCR-based assay for the detection and quantification of hepatitis E virus (HEV) RNA from across the entire spectrum of described genotypes belonging to the Orthohepevirus A genus. The optimal conditions and the performance of the assay were determined by testing the WHO standard strain (6219/10) and the WHO HEV panel (8578/13). Similarly, performance comparisons were made with two commercial assays (Real Star HEV RT-PCR 2.0 and ampliCube HEV 2.0 Quant) to detect HEV RNA at concentrations below 1,000 IU/ml with viral strains from the WHO and to test samples from 54 patients with acute hepatitis. The assay presented in this study was able to detect the entire spectrum of described genotypes belonging to the Orthohepevirus A genus, demonstrating better performance than both commercial kits. This procedure may represent a significant improvement in the molecular diagnosis of HEV infection.
PB American Society for Microbiology
YR 2020
FD 2020-10-22
LK http://hdl.handle.net/10668/16547
UL http://hdl.handle.net/10668/16547
LA en
NO Frías M, López-López P, Zafra I, Caballero-Gómez J, Machuca I, Camacho Á, et al. Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus (Orthohepevirus A Genus). J Clin Microbiol. 2021 Jan 21;59(2):e02075-20
NO This study was supported by the Fundación Progreso y Salud, Consejería de Saludde la Junta de Andalucía (PIN-0477/2017 and PI0187/2013); the Fundación para laInvestigación en Salud (FIS) del Instituto Carlos III (PI15/01017); and the Red deInvestigación en SIDA de España ISCIII-RETIC (RD16/0025/0034). A.R.-J. and M.F. arerecipients of postdoctoral perfection grants from the Spanish Ministry of Science,Innovation and Universities of Spain (CD18/00111 and CD18/00091, respectively).J.C.-G. is supported by a grant from the Spanish Ministry of Education, Culture andSport (FPU17/01319)
DS RISalud
RD Apr 9, 2025